|
||
Cyproterone acetate/Ethinylestradiol Uses |
||
androgen-associated acne, alopecia, hirsutism, and seborrhoea in women, combined oral contraceptive in women with androgenic symptoms
1 tab daily starting on the 1st day of menstrual cycle for 21 days followed by a tab-free interval of 7 days.
The efficacy of the contraceptive pill may be decreased in the case of irregular tablet-taking or when it is administered concomitantly with other medicines such as the anti-epileptic agents, antibiotics, barbiturates and rifampicin, and in patients with very rare individual metabolic disturbances (possible first symptom: intermenstrual bleeding). Mild laxatives do not impair the action of the tablets.
Oral contraceptive failure may occur with concomitant antibiotic therapy. For maximal protection, additional non-hormonal contraception should be recommended for the duration of antibiotic therapy and for seven days afterwards. Those on long-term antibiotic therapy need only take extra precautions for the first two weeks of antibiotic therapy.
Spotting and breakthrough bleeding are possible signs of diminished contraceptive effectiveness.
With vomiting or diarrhoea, the absorption of oral contraceptives may be diminished and women should be advised to use additional methods of contraception at the time of such disorders in order to prevent a possible pregnancy, which would be a compelling reason for the discontinuation of this medicine treatment.
Insulin and other hypoglycaemic requirements may change.
Effects on laboratory tests
Oral contraceptives may interfere with some laboratory estimations, in particular hormones, glucose tolerance, thyroid function, blood coagulation, serum triglycerides and liver function tests.
More common:
Less common:
Pregnancy; lactation; severe disturbances of liver function; recurrent cholestatic jaundice; jaundice or persistent itching during a previous pregnancy; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours; existing or previous thromboembolic processes in arteries or veins and states which predispose to such diseases (eg disturbances of the clotting system with a tendency towards thrombosis, certain heart diseases); severe migraine or cerebrovascular insufficiency; sickle-cell anaemia; existing or treated cancer of the breast or the endometrium; undiagnosed vaginal bleeding; severe diabetes with vascular changes; disturbances of lipometabolism; a history of herpes of pregnancy; otosclerosis with deterioration in previous pregnancies.
Cyproterone acetate/Ethinylestradiol
List of Cyproterone acetate/Ethinylestradiol substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Artemidis (Brazil) | |
Attempta (Germany) | |
Bella (Germany) | |
Bellgyn (Austria) | |
Biofem 35 (Argentina) | |
Ciprane (Brazil) | |
Co-cyproterone (Belgium) | |
Cypestra (Switzerland) | |
Cypronette (Germany) | |
Dialuna (Austria) | |
Diane-35 達英 (Hongkong) | |
Diane-35 tab 21's (Bayer) | |
Dianova (Denmark) | |
Doccyproestra (Belgium) | |
Estra Dian | |
Femogyn (Austria) | |
Merckelisa (Belgium) |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|